Palatin Technologies, Inc. (0KF3.L)

2,7200 -0,2980 (-9,87%) Alla chiusura: 05:39PM BST

Palatin Technologies, Inc.

Cedar Brook Corporate Center
4-B Cedar Brook Drive
Cranbury, NJ 08512
United States
609 495 2200
https://palatin.com

Settore/i: 
Settore: 
Impiegati a tempo pieno: 33

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Dr. Carl Spana Ph.D.	Co-Founder, Pres, CEO & Director	943,25k	N/D	1962
Mr. Stephen T. Wills CPA, CPA, MST	CFO, COO, Exec. VP, Treasurer & Sec.	870,57k	N/D	1957
Burns McClellan	VP of Investor Relations	N/D	N/D	N/D
Mr. Stephen A. Slusher Esq.	Chief Legal Officer	N/D	N/D	N/D
Dr. Michael B. Raizman M.D.	Chief Medical Officer	N/D	N/D	N/D
Mr. James E. Hattersley	Sr. VP of Bus. Devel.	N/D	N/D	1960
Mr. John Dodd Ph.D.	Sr. VP of Preclinical Devel.	N/D	N/D	N/D
Mr. Robert Jordan	Sr. VP of Program Operations	N/D	N/D	N/D

Gli importi risalgono al giorno 31 dicembre 2022 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.

Descrizione

Palatin Technologies, Inc., a biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States. The company's lead product is Vyleesi, a melanocortin receptor (MCr) agonist for the treatment of premenopausal women with hypoactive sexual desire disorder. It is also developing oral PL8177, a selective MC1r agonist peptide that has completed Phase I clinical trial for the treatment of inflammatory bowel diseases. In addition, the company engages in the development of PL9643, a peptide melanocortin agonist active at multiple MCrs, including MC1r and MC5r for anti-inflammatory ocular indications, such as dry eye disease; and melanocortin peptides for diabetic retinopathy. Further, it is developing PL3994, a peptide mimetic molecule with amino acid mimetic structure and amino acids properties; and L8177, an oral peptide formulation for treatment of ulcerative colitis, which entered Phase 2 clinical trials. The company was founded in 1986 and is based in Cranbury, New Jersey.

Governance aziendale

L'ISS Governance QualityScore di Palatin Technologies, Inc. al N/D è N/D. I criteri di valutazione fondamentali sono revisione: N/D; Consiglio di Amministrazione: N/D; diritti degli azionisti: N/D; retribuzione: N/D.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.